Pieris Pharmaceuticals Inc
NASDAQ:PIRS
Intrinsic Value
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. [ Read More ]
The intrinsic value of one
PIRS
stock under the Base Case scenario is
0.96
USD.
Compared to the current market price of 11.93 USD,
Pieris Pharmaceuticals Inc
is
Overvalued by 92%.
Pieris Pharmaceuticals Inc's market capitalization is 1.2B USD.
PIRS stock price is 11.93 USD.
PIRS stock (0.96 USD) is 92% less than its price (11.93 USD).
PIRS stock (1.8 USD) is 85% less than its price (11.93 USD). Open Relative Valuation
PIRS has downside potential of 40% compared to the average analyst price target.
Open Wall St Estimates
PIRS's ROE (Return on Equity) has decreased in the last 3 years from -86% to -90%, and is approaching profitability.
PIRS's Revenue has been growing by 13% per year for the last 3 years.
PIRS's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -89% to -77%, and is approaching profitability.
PIRS's Revenue has grown by an exceptional 65% over the past 12 months.
PIRS has negative Operating Income for the last twelve months.
PIRS has negative Net Income for the last twelve months.
PIRS's ROE (Return on Equity) for the past 12 months is negative and is equal to -90%.
PIRS's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -77%.
PIRS has negative Free Cash Flow for the last twelve months.
PIRS's short-term assets (39m USD) exceed its short-term liabilties (12m USD).
PIRS's long-term assets (39m USD) exceed its long-term liabilties (12m USD).
PIRS has negative three-year average ROE (Return on Equity): -93%. The company is not efficient at transforming stockholders' equity into net income.
PIRS has negative three-year average ROIC (Return on Invested Capital): -131%. The company is not efficient at using invested capital to generate operating income.
PIRS's D/E (Debt to Equity) is very low and is equal to 0.
PIRS's Altman Z-Score is very low and is equal to -10.73.
Valuation Backtest
Pieris Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
PIRS
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Pieris Pharmaceuticals Inc
Balance Sheet Decomposition
Pieris Pharmaceuticals Inc
| Current Assets | 38.7m |
| Cash & Short-Term Investments | 26.4m |
| Receivables | 6m |
| Other Current Assets | 6.3m |
| Current Liabilities | 11.9m |
| Accounts Payable | 3.4m |
| Accrued Liabilities | 8.2m |
| Other Current Liabilities | 363k |
Earnings Waterfall
Pieris Pharmaceuticals Inc
|
Revenue
|
42.8m
USD
|
|
Operating Expenses
|
-58.7m
USD
|
|
Operating Income
|
-15.8m
USD
|
|
Other Expenses
|
-8.7m
USD
|
|
Net Income
|
-24.5m
USD
|
Free Cash Flow Analysis
Pieris Pharmaceuticals Inc
PIRS Profitability Score
Profitability Due Diligence
Pieris Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Pieris Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
PIRS Solvency Score
Solvency Due Diligence
Pieris Pharmaceuticals Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Score
Pieris Pharmaceuticals Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PIRS Price Targets Summary
Pieris Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
PIRS
is 7.14 USD
with a low forecast of 7.07 USD and a high forecast of 7.35 USD.
Ownership
PIRS Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
PIRS Price
Pieris Pharmaceuticals Inc
| Average Annual Return | -8.19% |
| Standard Deviation of Annual Returns | 49.92% |
| Max Drawdown | -98% |
| Market Capitalization | 1.2B USD |
| Shares Outstanding | 98 850 000 |
| Percentage of Shares Shorted | 0.14% |
Company Profile
Pieris Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. The company is headquartered in Boston, Massachusetts and currently employs 124 full-time employees. The company went IPO on 2014-12-18. The Company’s clinical pipeline includes an inhaled IL-4Rα antagonist Anticalin protein to treat asthma, an immuno-oncology (IO), bispecific targeting HER2 and 4-1BB, and an IO bispecific targeting PD-L1 and 4-1BB. Its lead respiratory Anticalin-based drug candidate, PRS-060/AZD1402, which is antagonizes IL-4R alpha, thereby inhibiting by IL-4 and IL-13, two cytokines, which are small proteins mediating signaling between cells within the human body, known to be mediators in the inflammatory cascade that drive the pathogenesis of asthma and other inflammatory diseases. The lead IO Anticalin-based drug candidate in its pipeline, cinrebafusp alfa, which is designed to target the immune receptor 4-1BB and the tumor target HER2. Cinrebafusp alfa is a genetic fusion of a variant of an HER2-targeting antibody with an Anticalin protein.
Contact
IPO
Employees
Officers
The intrinsic value of one
PIRS
stock under the Base Case scenario is
0.96
USD.
Compared to the current market price of 11.93 USD,
Pieris Pharmaceuticals Inc
is
Overvalued by 92%.
You don't have any saved screeners yet
